CD274 and gastric cancer: As for survival, after integrating RCTs that reported the results of HR in patients with PD-L1 CPS ≥1 subgroup, we found borderline positive results of single-agent immunotherapy in gastric cancer, with 95% CI ranging from 0.74 to 0.96 in OS, while the pooled results in both allover and PD-L1 CPS <1 population were negative.